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Hepatocellular carcinoma (HCC) is one of the most common
tumours in the world and its prognosis is poor (Sherlock and
Dooley, 1997). However, the molecular mechanisms that lead to
the development and progression of HCC remain unclear.
Identification and characterization of specifically up- or down-
regulated genes in human HCC in comparison with the
surrounding non-tumorous tissue is useful for understanding
molecular changes in HCC and for developing diagnostic markers
and new potential therapeutic targets. 
Several methods have been reported for detecting differentially
expressed genes in tumorous tissues as compared with the corre-
sponding non-tumorous tissues, such as differential display (DD)
(Liang et al, 1992), expressed sequenced tags (EST) analysis
(Vasmatzis et al, 1998), subtractive hybridization (el-Deiry et al,
1993) and serial analysis of gene expression (SAGE) (Velculescu
et al, 1995). More recently, microarray technology attracted great
interest and continues to hold promise for studies on human
disease states (Khan et al, 1998; Alon et al, 1999). However, these
methods are often laborious and generally require a large amount
of mRNA, which is difficult to obtain from clinical materials,
especially from small HCC specimens. 
In the present study, in order to screen differentially expressed
genes efficiently from small clinical specimens of HCC, we
utilized suppression subtractive hybridization (SSH) (Diatchenko
et al, 1996; von Stein et al, 1997) combined with modified RT-
PCR technology (Matz et al, 1999). Although several studies using
SSH have successfully identified the differentially expressed
genes in a variety of disease states (Kuang et al, 1998; Stubbs et al,
1999), the present study is the first report to identify the altered
gene expression profiles in HCC by SSH. 
MATERIALS AND METHODS 
Tissue samples 
We used an HCC sample (moderately differentiated hepatocellular
carcinoma) and an adjacent non-HCC liver tissue sample, both
obtained during surgery from a 56-year-old man infected with
hepatitis C virus, for the initial SSH analysis. The HCC was 3 cm
in diameter and the histology of non-HCC tissue was consistent
with chronic hepatitis, with moderate inflammatory activity and
severe fibrosis. The other 9 pairs of HCC and adjacent non-HCC
tissues were obtained at surgery or needle biopsy. In all, 10 pairs of
HCC and non-HCC samples were enrolled in this study, of which
8 cases were infected with hepatitis C virus, while the other 2
cases were due to hepatitis B virus and primary biliary cirrhosis.
Among the 10 cases, 4 well-differentiated adenocarcinomas, 5
moderately differentiated adenocarcinomas, and one poorly differ-
entiated adenocarcinoma were present. Written informed consent
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was obtained from each patient before liver biopsy or surgery, and
the study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki. In addition, institutional approval was
obtained. 
RNA extraction and SMART™ cDNA synthesis 
Total RNA was extracted by the modified acid-guanidium-chloro-
form method (Chomczynski et al, 1987) using ISOGEN™
(Nippon Gene, Toyama, Japan) and according to the manufac-
turer’s instruction. We generated cDNA from the total RNA
samples from 10 pairs of HCC and adjacent non-HCC samples
using the SMART™ (Switch Mechanism at 5¢ end of RNA
Template) PCR cDNA synthesis kit (Clontech, Palo Alto, CA).
The SMART™ cDNA synthesis technology (Matz et al, 1999)
utilizes a combination of 2 primers in a single reaction. Briefly,
1 mg of total RNA was reverse-transcribed in 10 ml mixture with
200 U of Superscript™ reverse transcriptase (Gibco, Madison,
WI) using 10 mM of modified oligo dT primer (CDS primer;
5¢AAGCAGTGGTAACAACGCAGAGTACT30(AGC)(AGCT)
and SMART™ primer (5¢AAGCAGTGGTAACAACGCAGAG-
TACGCGGG). The CDS primer is used to prime the first-strand
reaction, while the SMART™ oligonucleotide serves as a short,
extended template at the 5¢ end of the RNA template. When the
reverse transcriptase reaches the 5¢ end of the mRNA, the
enzyme’s terminal transferase activity adds a few additional
deoxycytidines to the 3¢ end of the cDNA. The SMART™
oligonucleotide, which has an oligo (G) sequence at its 3¢ end,
base-pairs with the deoxycytidine stretch, creating an extended
template. The enzyme switches templates and continues repli-
cating to the end of the SMART™ oligonucleotide. The resulting
full-length, single-stranded cDNA contains the complete 5¢ end of
the mRNA and the sequence complementary to the SMART™
oligonucleotide, which then serves as a long distance PCR priming
site to amplify the full-length cDNA. The first-strand of cDNA
was diluted to a final volume of 50 ml with 1 ´ TE buffer (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA). One ml of the diluted cDNA was
used to generate the cDNA by long distance PCR with
Advantage™ Klen Taq polymerase mix (Clontech, Palo Alto,
CA), using PCR primer (5¢ AAGCAGTGGTAACAACGCAGA)
following the manufacturer’s instructions. 
Suppression subtractive hybridization (SSH) 
SSH was performed with the PCR-Select™ cDNA Subtraction
Kit (Clontech, Palo Alto, CA) according to the manufacturer’s
protocol, except for slight modifications as below. SMART™
cDNA derived from HCC and non-HCC tissues were digested by
RsaI restriction enzymes to obtain blunt-ends which are necessary
for adaptor ligation. RsaI digested cDNA was purified using the
QIA quick™ PCR Purification Kit (Qiagen, Chatsworth, CA).
Tester cDNA was divided into two and ligated separately with 2
different adaptors, and cDNA without adaptors was used as a
driver. 0.25 ng of tester cDNA with an excess amount (150 ng) of
driver cDNA were hybridized in one ml of hybridization mixture at
65˚C for 16 hours. The 2 hybridization solutions and 150 ng of a
fresh driver cDNA were then mixed and incubated at 65˚C for
additional 8 hours, so that the remaining equalized single-stranded
tester cDNA was hybridized with excess driver cDNA. Thus, only
tester-specific cDNA formed the double-stranded cDNA with
different adaptors on each end. They were selectively amplified by
suppression PCR followed by the nested PCR, which does not
exponentially amplify the non-adaptor (derived from driver
cDNA), cDNA with the one adaptor on either end (derived from
tester cDNA hybridized with driver cDNA), or cDNA with the
same adaptor on both ends (derived from relatively abundant tester
cDNA). 
Cloning and sequencing 
10 ng of PCR products were cloned into plasmids pGEM-T Easy
Vector™ (Promega, Madison, WI) and transformed to competent
E. coli XL2-blue™ Ultracompetent cells (Stratagene, Ceder Creek,
TX). 100 colonies were randomly picked up and sequenced using
the PRISM dye termination kit™ (ABI, Chiba, Japan). BLAST
Search 2.0 (www.ncbi.nlm.nih.gov/blast/blast.cgi) was used to
analyse sequence homologies in the gene database. For sequences
with no significant homology to the database, we performed 3¢ and
5¢-rapid amplification of cDNA ends (RACE) in order to obtain
the full-length cDNAs of these transcripts using a Marathon
cDNA Amplification kit™ (Clontech, Palo Alto, CA) according to
the manufacturer’s protocol. 
Immunohistochemistry 
Immunohistochemical staining was performed in the index HCC
and surrounding non-HCC tissue with 5 mm thick sections from
formalin-fixed, paraffin embedded blocks, using the labelled
streptavidin biotin immunohistochemical staining method, in
order to confirm the differential expression of these genes in the
original case. Sections were incubated with anti-pepsinogen C
antibody (Biogenesis, Poole, UK), anti-GS antibody, anti-FAK
antibody, and anti-DCC antibody (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA) at a dilution of 1:100 overnight at 4˚C. Then,
tissue sections were exposed to biotin-labelled anti-mouse IgG
(DAKO, Glostrup, Denmark) for reaction with pepsinogen C, and
anti-goat IgG (DAKO, Glostrup, Denmark) for glutamine
synthetase for 30 min at room temperature and then with strepta-
vidin (DAKO, Glostrup, Denmark). Visualization was performed
by using 3,3¢-diaminobenzidine and H2O2 and counterstained with
haematoxylin. 
Quantitative analysis of overexpressed genes 
Overexpression of the obtained genes was confirmed by semi-
quantitative RT-PCR, comparing the amount of PCR products
by agarose gel electrophoresis at the PCR cycle number in the
exponential phase of amplification as indicated in Figure 5.
Subsequently, the mRNA expression levels of these genes were
quantitated by competitive RT-PCR using gene-specific deleted
cDNA competitors (Zachar et al, 1993) (focal adhesion kinase,
deleted in colon cancer, glutamine synthetase, ornithine amino-
transferase, guanine binding inhibitory protein, and M130) or by
the real-time PCR (pepsinogen C and decorin) using the Light
Cycler System™ (Roche Diagnostics, Manheim, Germany)
(Wittwer et al, 1997). Expression of each mRNA, standardized
with glyceroaldehyde-3-phospho-dehydrogenase (G3PDH)
expression, was compared in 10 pairs of HCC and adjacent non-
HCC tissues. The primers used in the quantitative PCR were
shown in Table 1. 230 Y Miyasaka et al
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RESULTS 
SMART™ RT-PCR 
From 20 ng of total RNA, 1–2 mg of cDNA were generated by the
SMART™ RT-PCR protocol, yielding a smear of cDNA from 0.5
to 6 kb with many bright bands corresponding to relatively abun-
dant transcripts on agarose gel electrophoresis (data not shown). 
SSH 
In order to evaluate the efficiency of our SSH method, we created
the artificial tester HCC cDNA in which bacteriophage fc174/
HaeIII DNA was added, so that each fragment of fc174
DNA corresponded to about 0.02% (1/5000) of the HCC cDNA.
Using the HCC cDNA by itself without fc174 DNA as the driver,
SSH was carried out. DNA fragments derived from fc174 DNA
were successfully amplified by SSH, indicating that our SSH
method could detect the differentially expressed gene with as little
as 1/5000 of tester cDNA (data not shown). 
After SSH using HCC cDNA as a tester, there remained approx-
imately 10 bands as a second PCR product on agarose gel elec-
trophoresis (Figure 1). The nucleotide sequences of 100 clones
obtained from this PCR product were analyzed by a BLAST 2.0
database homology search. Seven known genes, pepsinogen C
(PGC, Gene Bank Accession Number, P20142), focal adhesion
kinase (FAK, Q05397), glutamine synthetase (GS, P43146), M130
(VI38005), guanine binding inhibitory protein a (Gia, P08754),
deleted in colon cancer (DCC, P43146), and ornithine aminotrans-
ferase (OAT, P04181) were repetitively detected in 100 randomly
selected clones (Table 2). Two sequences (arbitrarily designated as
HCC-1 and HCC-2), without significant homology to genes within
the database, were also repeatedly isolated. The sequence analysis
of RACE products from these clones revealed weak homologies to
retrotransposon MARINER (U49974) and LINE-1 (B28096),
respectively (Figure 2). Using non-HCC cDNA as a tester, decorin
(P07585) was identified as suppressed in HCC. 
Confirmation of differentially expressed genes by 
semi-quantitative RT-PCR 
Differential expression of genes detected in SSH analysis were
confirmed in original HCC and non-HCC tissues by semi-
quantitative RT-PCR as shown in Figure 3. PCR products in the
exponential phase of amplification were analysed by agarose gel
electrophoresis, which compared the amount of specific products
Table 1 Primer sequences 
Primer name Sequence 
FAK forward 5¢ TTCATTATTTTGAAAGCAATAGT3¢
FAK reverse 5¢ CAACCCAACTTCAAAGCAATTTC3¢
FAK forward competitor 5¢ TGCCTATTAAATGGATGGCTCCAATGGTGTGAAGCCTTTTCAA3¢
DCC forward 5¢ CGAGTTGTGGCTTACAATGAATGG3¢
DCC reverse 5¢ CCACTTCCAGGGAGACGTTCTGAG3¢
DCC forward competitor 5¢ CGAGTTGTGGCTTACAATGAATGGTGCAAGCTGTATCTACCTCA3¢
GS forward 5¢ GTACTCTGGTTAGGTTAGGACTT3¢
GS reverse 5¢ TTCTAATCCGACTATTTGTCTCA3¢
GS forward competitor 5¢ GTACTCTGGTTAGGTTAGGACTTGTAGGGGTTGGGAATCAGAG3¢
OAT forward 5¢ GGGAGCATGGGTCCACATACGGT3¢
OAT reverse 5¢ CACATCAAAACACTTCAACTGAA3¢
OAT forward competitor 5¢ GGGAGCATGGGTCCACATACGGTAAAATGCAGACAAATTGGGC3¢
Gia forward 5¢ GCCCTCTCACTATATGCTATCCA3¢
Gia reverse 5¢ ACTCATTTGGTTTGAAAATGCA3¢
Gia forward competitor 5¢ GCCCTCTCACTATATGCTATCCAGGACACAAAGGAAATATACA3¢
M130 forward 5¢ ACGCTGGGGCCATAGTGAGTGTG3¢
M130 reverse 5¢ ACAGACCTGAGGAATTCATTAGG3¢
M130 forward competitor 5¢ ACGCTGGGGCCATAGTGAGTGTGCTCATCCCGTCAGTCATCCT3¢
PGC forward 5¢ CAGCTTGACCTTCATCATCAATG3¢
PGC reverse 5¢ CCAGAGTGGAAAGACAGATACAA3¢
Decorin forward 5¢ AAATAACTGAAATCAAAGATGGAGA3¢
Decorin reverse 5¢ TAAGAGAAGGAGGAAGACCTTGAGG3¢
HCC specific
Subtracted
cDNA
Unsubtracted cDNA
Rsa l digest
Non-HCC HCC
-2000 bp
-1000 bp
-500 bp
-100 bp
Figure 1 SMARTTM cDNA after Rsa I digestion of HCC and non-HCC
cDNA, and nested PCR products of SSH on electrophoresis on 2.0% 
agarose/EtBr gel Subtraction cloning of HCC associated genes 231
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at the minimal number of PCR cycles for visualization on agarose
gels. Amplification of representative house-keeping genes,
G3PDH and b-actin, were similar between the HCC and non-HCC
tissues. Target products of genes obtained from HCC were clearly
amplified from HCC cDNA, whereas only weak or no amplifica-
tion occurred from non-HCC cDNA at the same PCR cycles.
Conversely, decorin was amplified more efficiently from non-
HCC tissue than from HCC tissue. 
Quantitative analysis of differentially expressed genes
in HCC 
The expression levels of mRNA of these 8 known genes were
quantitated in 10 pairs of HCC and non-HCC tissues, including the
original samples used in SSH. SMART™ cDNAs were generated
from each sample, and used as templates of quantitative PCR. The
quantity of cDNA copies were standardized with those of G3PDH
in each sample. The ratio of each gene in HCC tissue compared to
non-HCC tissue is shown in Figure 4. The expression levels of
these genes were not always over the detection limits of the PCR
assay in all 10 pairs. When the expression level of the target cDNA
was under the detection limits in HCC, the ratio was considered to
be 0. When the expression in non-HCC tissue was under the detec-
tion limits, the ratio was calculated by dividing the value for HCC
by the detection limits of the target gene. The HCC/non-HCC ratio
could not be available when the target cDNA could not be quanti-
tated in both HCC and non-HCC tissues of the same patient
(2 cases for FAK, 1 case for DCC, 2 case for GS, 1 case for Gia,
2 cases for OAT, 4 cases for M130 and 5 cases for PGC). FAK was
overexpressed in HCC compared to non-HCC by more than 2-fold
in 4 of 8 cases (2–8.5 folds), DCC in 5 of 9 (2.2–14 folds), GS in 5
of 8 (2–63 folds), Gia in 5 of 9 (8.6–149 folds), OAT in 5 of 8
(2.3–8.3 folds), M130 in 1 of 6 (8.4 folds), PGC was in 5 of 5 cases
(5.7–70700 folds). Decorin was suppressed in 8 of 9 cases (2–266
folds). There was no correlation between mRNA levels of the
identified genes and the aetiology or the histological grade of
tumours. 
Immunohistochemistry 
The immunohistochemical analyses for PGC and GS revealed
positive staining in hepatoma cells, whereas no apparent signals
were detectable in non-HCC tissue (Figure 5). FAK and DCC
Figure 2 Alignment of HCC-1 with human and insect MARINER
transposase, and HCC-2 with human LINE-1. Identical amino acids are
shown between the sequences. A (+) sign indicates a conservative
replacement. Insect MARINER is the milkweed bug transposon mariner
(Genebank Accession No. S37012), and human sequence is the human
MARINER (U49974). LINE-1 sequence is derived from line-1 protein open
leading frame 2 (B28096). The numbers indicate the amino acid positions in
each protein. Multiple stop codons indicated by asterisks implicate HCC-2 as
an inactive LINE-1 homologue 
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Figure 3 Confirmation of expression in original HCC by semi-quantitative
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Figure 4 Gene expression ratio of HCC to non-HCC in paired samples.
Expression of each gene was standardized with the expression of G3PDH in
each sample. Closed circles represent the cases in which the gene
expression ratio of HCC to non-HCC was greater than 2 (except decorin),
and open circles less than 2. For decorin, closed circles indicate the cases
whose expression ratio of non-HCC/HCC was greater than 2, and open
circles correspond to cases whose ratio was less than 2. The numbers
beside the circles indicate the ratios in values 
Table 2 Sequence analysis of 100 clones isolated from subtracted HCC
cDNA 
Gene Number of clones 
HCC-1a 11 
Focal adhesion kinase (FAK) 8 
Glutamine synthetase (GS) 6 
M130 3 
HCC-2a 3 
Guanine binding protein ia (Gia)2  
Deleted in colon cancer (DCC) 2 
Ornithine aminotransferase (OAT) 2 
Miscellaneous 43 
Total 100 
a Two previously unidentified genes showing no significant homology to
genes within the database were designated arbitrarily as HCC-1 and -2. 232 Y Miyasaka et al
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could not be detected in either HCC or non-HCC tissue (data not
shown), probably because their absolute expression levels were
too low to be detected by immunostaining. 
DISCUSSION 
Although many studies have analysed genes differentially
expressed in tumour tissues compared to non-tumorous liver
tissue, the comprehensive picture of HCC-specific gene expres-
sion has not been revealed. In the present study, we applied the
novel subtractive suppression hybridization technique combined
with the SMART™ RT-PCR method in order to identify the differ-
entially expressed genes between HCC and non-HCC tissue. As a
result, 7 genes were identified as up-regulated and one gene as
down-regulated in HCC. In addition, overexpression of 2 previ-
ously unknown genes showing weak homology with retrotrans-
poson sequences were also detected. Differential expression of
these genes in the index case was demonstrated by the semi-
quantitative RT-PCR assay, and increased protein expression of
GS and PGC tissue was also confirmed by immunohistochemistry.
Quantitative analysis of gene expression using RT-PCR demon-
strated the differential expression of these genes in other HCC
samples as well as the index sample. Interestingly, most of these
genes are associated with HCC or other cancers as described
below. Identification of such genes showing altered expression in
HCC would be useful step in understanding the molecular patho-
genesis of HCC, in developing specific tumor markers, and in
designing potentially novel therapeutic directions. 
Generally, it is estimated that approximately 20 000 genes are
expressed in an individual cell (Zhang et al, 1997), and previous
SAGE (Zhang et al, 1997) or high-density microarray (Alon et al,
1999) data have suggested that the proportion of genes whose
expression levels in tumours is higher or lower than 10-fold in
comparison to normal tissues account for as much as 0.5–2% of
mRNA species (Zhang et al, 1997). Such small differences in gene
expression between cancer and its origin tissue were also
suggested by the present observation that electrophoretic bands of
HCC SMART™ cDNA closely resembled that of non-HCC
SMART™ cDNA. SSH technique seems to be sensitive enough to
detect differentially expressed genes of such low abundance,
because in the control experiment that used spiked fX174 DNA
consisting of 0.02% of tester cDNA could be easily recovered by
SSH using non-spiked cDNA as a driver. SSH involves a process
called normalization, which equalizes the relative amount of each
cDNA species in the hybridization step (Diatchenko et al, 1996).
This process avoids preferential isolation of genes with high abun-
dance. Thus, differentially expressed genes with low abundance
can be detected sensitively, making this procedure more simple
and effective than traditional subtraction. In addition, it has been
extensively validated by other investigators (Endege et al, 1999)
that SMART™ cDNA products can maintain the original message
profile from a small amount of RNA. 
Out of 7 known genes identified as upregulated in HCC, 2 
genes (GS and Gia) were well-established as overexpressed 
in HCC (Christa et al, 1994, et al, 1997). GS is a ubiquitous
enzyme that catalyzes the synthesis of glutamine from glutamate
and ammonia at the expense of ATP. Overexpression of GS mRNA
in HCC has been reported previously (Christa et al, 1994), and 
its role in promoting metastasis was suggested (Osada et al, 1999).
Gia is a subunit of guanine-binding inhibitory protein that inhibits
adenylate cyclase and is known to be involved in cell growth,
differentiation, apoptosis. 5 other known genes detected in 
this study were not previously reported as being up-regulated in
HCC. 
PGC is a proteolytic enzyme that digests proteins in the stomach
and is also involved in gastric epithelial cell growth during gastric
mucosal healing (Kishi et al, 1997). It is produced not only in
stomach, but also in breast cancer (Diez-Itza et al, 1993) and
prostate cancer (Konishi et al, 1999), and is implicated in the lytic
processes of invasive cancer lesions. Extragastric expression of
PGC is partially regulated with a minimal promoter region that is
found in androgen-regulated genes (Balbin and Lopez-Otin,
1996). Actually, in breast cancer and prostate cancer, expression of
PGC is closely associated with androgen receptor status (Diez-Itza
et al, 1993; Konishi et al, 1999), indicating that PGC expression is
regulated by androgens in these tumours. HCC is a male predomi-
nant disease and expresses the androgen receptor (Nagasue et al,
1995), suggesting that the expression of PGC in HCC might be
also up-regulated by androgens. Although the role of PGC in HCC
is still unknown, the common pathway of tumour growth or
tumorigenesis between HCC and other PGC-producing cancers
may be found. 
FAK is a signal transducer of integrins and some soluble growth
factors. FAK becomes phosphorylated and activated during
integrin-mediated cell adhesion, of which signal allows cells to
sense adherence to the extracellular matrix, thus providing a cell
survival signal and preventing apoptosis (Frisch et al, 1996). Cells
which express FAK show increased migration relative to wild-type
cells (Kornberg, 1998). FAK has been reported to overexpress in
invasive and metastatic colon (Weiner et al, 1993), thyroid (Owens
et al, 1996) and prostate cancers (Tremblay et al, 1996), but its
overexpression in mRNA or protein level has never been reported
in HCC. Although mechanisms of up-regulation of FAK is
unknown, overexpression of FAK leads to increased cell migration
and increased cell survival under anchorage-independent condi-
tions (Weiner et al, 1993), which might be advantageous to HCC
growth and invasion. Further work is needed to determine whether
FAK represents a therapeutic target for invasive HCC. We found
no mutations via sequencing analysis of the full length of FAK as
well as PGC cDNA obtained from the original HCC sample,
suggesting as for the index case that overexpression of these genes
was not a compensatory mechanism for inactivating mutations. 
A C
B D
Figure 5 Immunohistochemistry for PGC and GS in HCC and non-HCC
tissue used for SSH analysis. These gene products were specifically stained
in hepatoma tissues compared to non-hepatoma tissues. GS in hepatoma
cells (A). GS in non-hepatoma cells (B). PGC in hepatoma cells (C). PGC in
non-hepatoma cells (D) Subtraction cloning of HCC associated genes 233
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The DCC gene codes a protein with significant sequence simi-
larity to neural cell adhesion molecules, a transmembrane protein
of the immunoglobulin superfamily, which is thought to be a
receptor for netrin-1 (Fazeli et al, 1997). DCC induces apoptosis in
the absence of netrin-1 leading to the inhibition of metastasis or
invasion beyond local blood supply (Mehlen et al, 1998). While
the DCC gene was expressed in normal colonic mucosa or non-
metastatic colon cancers, its expression was greatly reduced in
invasive or metastatic adenocarcinomas with unfavourable prog-
noses (Gotley et al, 1996). In normal tissues, DCC protein is abun-
dant in bladder tissue, and is detectable in colon, pancreas, and
kidney, but not in normal liver tissue (Gotley et al, 1996).
Therefore, retained expression of DCC in HCC found in this study
might prevent hepatoma cells from invasion and metastasis. In
fact, the index case was obtained from a primary lesion with no
distant metastasis (Mehlen et al, 1998). DCC expression within
metastatic hepatomas should be examined in order to elucidate the
preventive role of DCC in HCC progression. 
The relationship between hepatocarcinogensis and the other 2
detected genes, OAT and M130 is rather unclear. OAT catalyses
the transamination of ornithine to glutamate, substrate of GS in the
liver (Kuo and Darnell, 1991). M130 is a macrophage differentia-
tion antigen which is a member of the scavenger receptor super-
family (Ritter et al, 1999) and differential expression in
mesothelial cancer was reported (Frank et al, 1998). 
On the contrary, SSH analysis of non-HCC minus HCC identi-
fied decorin as being down-regulated in HCC, which was
suppressed in 8 of 9 HCC tissues examined. Decorin is a small
proteoglycan, and is known to inhibit transforming growth facter-
b (TGF-b) by binding to it, and may directly interfere with the cell
cycle via induction of cyclin-dependent protein kinase, p21
(Stander et al, 1999). It has been reported that decorin suppresses
tumorigenicity when expressed in colon cancer cells (Santra et al,
1995), but the association with HCC has not yet been elucidated.
The present results suggest that decorin might have an inhibitory
effect on HCC tumorigenesis or progression. Further studies on
the role of decorin in hepatocarcinogenesis are warranted. 
Two previously unknown genes, HCC-1 and HCC-2, were
found to be overexpressed in HCC and showed weak homologies
to the retrotransposon sequences, MARINER (Robertson et al,
1996; Plasterk et al, 1999) and LINE-1 (Skowronski et al, 1988;
Bratthauer and Fanning, 1992), respectively. Although in murine
hepatoma models both carcinogen-induced and spontaneous liver
tumour formation is associated with abnormalities in the expres-
sion of endogenous retrovirus-related DNA sequences (Dragani
et al, 1986), the actual function of HCC-1 and HCC-2 in HCC is
unknown and awaits the further characterization. 
Since the case analysed by SSH was moderately differentiated
carcinoma, the detected genes might be overexpressed specifically
in moderately differentiated HCC. HCC of other differentiation
grade tumours may possess different expression profiles from the
one obtained in this study, thus different stages of HCC should be
analysed to elucidate the complete picture of the stage-specific
gene expressions. 
In conclusion, SSH showed that PGC and FAK are overex-
pressed and decorin is suppressed in HCC, demonstrating that it is
applicable for revealing the previously unknown, differential gene
expression from a small clinical samples. The information of such
alterations in gene expression could be useful for elucidating the
genetic events in HCC pathogenesis and developing the new diag-
nosic marker or therapeutic targets. 
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